News
CPRX
20.00
+0.60%
0.12
Capricor stock rallies 20% on DMD data presentation update
Seeking Alpha · 2d ago
Catalyst (CPRX) is on the Move, Here's Why the Trend Could be Sustainable
NASDAQ · 4d ago
Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock?
NASDAQ · 5d ago
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
Barchart · 5d ago
Weekly Report: what happened at CPRX last week (0923-0927)?
Weekly Report · 6d ago
Catalyst Pharmaceuticals: High Valuation Amid Weak Long-Term Prospects (Rating Downgrade)
Seeking Alpha · 09/24 13:28
Catalyst Pharma's Sub-licensee, DyDo, Secures Regulatory Approval For FIRDAPSE In Japan
NASDAQ · 09/24 10:43
Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")
Benzinga · 09/24 10:08
CATALYST PHARMACEUTICALS ANNOUNCES SUB-LICENSEE DYDO PHARMA RECEIVED APPROVAL TO COMMERCIALIZE FIRDAPSE® IN JAPAN
Reuters · 09/24 10:02
Weekly Report: what happened at CPRX last week (0916-0920)?
Weekly Report · 09/23 10:29
FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks
NASDAQ · 09/21 08:15
EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot?
NASDAQ · 09/20 07:15
Weekly Report: what happened at CPRX last week (0909-0913)?
Weekly Report · 09/16 10:23
Weekly Report: what happened at CPRX last week (0902-0906)?
Weekly Report · 09/09 10:29
Dyne stock tumbles 31% amid drug updates, management changes
Seeking Alpha · 09/03 20:48
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today
NASDAQ · 09/02 12:30
Weekly Report: what happened at CPRX last week (0826-0830)?
Weekly Report · 09/02 10:32
Weekly Report: what happened at CPRX last week (0819-0823)?
Weekly Report · 08/26 10:30
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Barchart · 08/20 07:03
Weekly Report: what happened at CPRX last week (0812-0816)?
Weekly Report · 08/19 10:22
More
Webull provides a variety of real-time CPRX stock news. You can receive the latest news about Catalyst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.